跳至主要内容
临床试验/JPRN-UMIN000044192
JPRN-UMIN000044192已完成未知

The actual condition of combined use of topical preparations in oral 5-ASA preparation treatment for ulcerative colitis. - The actual condition of combined use of topical preparations in oral 5-ASA preparation treatment for ulcerative colitis.

MOCHIDA PHARMACEUTICAL CO., LTD.0 个研究点目标入组 2,247 人开始时间: 2021年5月12日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
2,247

研究概览

简要总结

The combination proportion of oral therapy with 5-ASA (OT5ASA) and topical therapy (TT) were 21.5 and 21.6% in cohorts 1 (OT5ASA only at the first prescribing) and 2 (TT only), respectively, with no differences between cohorts and medicines. For the proportion of subjects, which prescribing initiation was OT5ASA, with <25% of TT combinations, proportion of time-dependent, pH-dependent and MMX was 28.4, 28.1 and 42.9%, respectively, and OT5ASA continuation proportion were 46.9, 44.9 and 65.9%, respectively.

研究设计

研究类型
Observational

入排标准

年龄范围
16years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. The following diagnostic or implementation records for 6 months from the previous month of the Index and for the next 13 months including the Index. -Crohn's disease -Colorectal cancer -Total and subtotal resection of the colorectal and colon 2. Oral 5-ASA prescriptions outside the approved dose range for the next 13 months, including Index date. 3. Records of unknown prescription dates for oral 5-ASA and topical preparations in the next 13 months, including the Index date. 4. Prescription with unknown drug name or standards for oral 5-ASA and topical preparations in the next 13 months, including the Index date.

研究者

相似试验